细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5286人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702454, encodeId=a8431e02454c4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, objectType=article, longId=123207, objectId=4dfc12320e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfc12320e42, replyNumber=0, likeNumber=40, createdTime=2017-12-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfc12320e42, moduleTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dfc12320e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702428, encodeId=a3601e024280d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=“淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)”解读, objectType=article, longId=112893, objectId=de7e11289344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de7e11289344, replyNumber=0, likeNumber=23, createdTime=2017-11-02, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de7e11289344, moduleTitle=“淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)”解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de7e11289344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702431, encodeId=a9261e0243180, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2017.V4）, objectType=article, longId=114223, objectId=f5351142232b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5351142232b, replyNumber=0, likeNumber=23, createdTime=2018-05-16, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5351142232b, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2017.V4）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5351142232b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702427, encodeId=2ab81e0242733, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Am J Hematol：来那度胺单药治疗复发性/难治性套细胞淋巴瘤, objectType=article, longId=111593, objectId=0e981115938d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e981115938d, replyNumber=0, likeNumber=53, createdTime=2017-09-30, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e981115938d, moduleTitle=Am J Hematol：来那度胺单药治疗复发性/难治性套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e981115938d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702461, encodeId=f9a01e02461ab, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Duvelisib与免疫检查点抑制剂在B细胞淋巴瘤模型中具有显著协同作用, objectType=article, longId=128118, objectId=6f21128118f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f21128118f9, replyNumber=0, likeNumber=55, createdTime=2018-03-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f21128118f9, moduleTitle=Duvelisib与免疫检查点抑制剂在B细胞淋巴瘤模型中具有显著协同作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f21128118f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702481, encodeId=0a711e0248188, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=伴面部肿胀结外鼻型NK/T细胞淋巴瘤死亡1例, objectType=article, longId=135294, objectId=273b1352945b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=273b1352945b, replyNumber=0, likeNumber=63, createdTime=2018-12-19, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=273b1352945b, moduleTitle=伴面部肿胀结外鼻型NK/T细胞淋巴瘤死亡1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=273b1352945b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702455, encodeId=ff0f1e0245580, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=蔡清清教授：套细胞淋巴瘤治疗新进展综述, objectType=article, longId=123280, objectId=978a12328040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=978a12328040, replyNumber=0, likeNumber=146, createdTime=2018-10-30, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=978a12328040, moduleTitle=蔡清清教授：套细胞淋巴瘤治疗新进展综述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=978a12328040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702471, encodeId=313b1e024713e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=69, createdTime=2018-08-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702419, encodeId=7abe1e024190e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性, objectType=article, longId=106516, objectId=1980106516d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1980106516d2, replyNumber=0, likeNumber=59, createdTime=2017-09-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1980106516d2, moduleTitle=Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1980106516d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702446, encodeId=821e1e02446ad, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2017.V6）, objectType=article, longId=120750, objectId=13e5120e508a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13e5120e508a, replyNumber=0, likeNumber=25, createdTime=2018-04-15, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13e5120e508a, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2017.V6）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13e5120e508a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702410, encodeId=c9fa1e02410f7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Leuk Lymphoma：体重指数可以预测弥漫性大B细胞淋巴瘤的结局吗？, objectType=article, longId=97762, objectId=904e9e7626b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904e9e7626b, replyNumber=0, likeNumber=90, createdTime=2017-10-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904e9e7626b, moduleTitle=Leuk Lymphoma：体重指数可以预测弥漫性大B细胞淋巴瘤的结局吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904e9e7626b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702411, encodeId=ec4a1e0241170, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：弥漫性大B细胞淋巴瘤的tonic BCR信号通路。, objectType=article, longId=103296, objectId=e8f51032963e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8f51032963e, replyNumber=0, likeNumber=70, createdTime=2017-10-20, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8f51032963e, moduleTitle=Blood：弥漫性大B细胞淋巴瘤的tonic BCR信号通路。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8f51032963e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702447, encodeId=4b3b1e0244723, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究, objectType=article, longId=120900, objectId=190612090080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=190612090080, replyNumber=0, likeNumber=105, createdTime=2018-07-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=190612090080, moduleTitle=【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=190612090080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Haematologica：ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加, objectType=article, longId=105447, objectId=bba010544edd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bba010544edd, replyNumber=0, likeNumber=65, createdTime=2018-05-16, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bba010544edd, moduleTitle=Haematologica：ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bba010544edd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702432, encodeId=ef441e024328b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NEJM：套细胞淋巴瘤患者自体干细胞移植后使用利妥昔单抗维持治疗可延长反应时间, objectType=article, longId=114848, objectId=852411484844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=852411484844, replyNumber=0, likeNumber=99, createdTime=2017-10-23, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=852411484844, moduleTitle=NEJM：套细胞淋巴瘤患者自体干细胞移植后使用利妥昔单抗维持治疗可延长反应时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=852411484844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702420, encodeId=05ad1e024208c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Am J Hematol：来那度胺单药治疗复发性/难治性套细胞淋巴瘤，安全且有效, objectType=article, longId=107096, objectId=7f2310e09663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f2310e09663, replyNumber=0, likeNumber=87, createdTime=2017-12-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f2310e09663, moduleTitle=Am J Hematol：来那度胺单药治疗复发性/难治性套细胞淋巴瘤，安全且有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f2310e09663)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702442, encodeId=23701e0244205, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=天津血液肿瘤高峰论坛 |张翼鷟教授：弥漫大B细胞淋巴瘤造血干细胞移植进展, objectType=article, longId=119213, objectId=fdee11921374, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdee11921374, replyNumber=0, likeNumber=67, createdTime=2018-01-25, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdee11921374, moduleTitle=天津血液肿瘤高峰论坛 |张翼鷟教授：弥漫大B细胞淋巴瘤造血干细胞移植进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdee11921374)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702437, encodeId=17d91e0243714, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【CSCO 2017】黄慧强教授专访：浅谈套细胞淋巴瘤的治疗及BTK抑制剂的疗效, objectType=article, longId=116549, objectId=be6711654932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6711654932, replyNumber=0, likeNumber=77, createdTime=2018-07-23, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6711654932, moduleTitle=【CSCO 2017】黄慧强教授专访：浅谈套细胞淋巴瘤的治疗及BTK抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be6711654932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702460, encodeId=27071e024608c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=ANN ONCOL：Ⅰ/Ⅱ期NK/T细胞淋巴瘤序贯化疗/放疗与同时放化疗效果相似, objectType=article, longId=128008, objectId=63581280084d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63581280084d, replyNumber=0, likeNumber=103, createdTime=2018-11-18, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63581280084d, moduleTitle=ANN ONCOL：Ⅰ/Ⅱ期NK/T细胞淋巴瘤序贯化疗/放疗与同时放化疗效果相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63581280084d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702426, encodeId=729c1e024267b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：携带TP53突变的套细胞淋巴瘤患者对现有疗法没有反应。, objectType=article, longId=109240, objectId=9dcd109240f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd109240f3, replyNumber=0, likeNumber=71, createdTime=2017-11-23, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd109240f3, moduleTitle=Blood：携带TP53突变的套细胞淋巴瘤患者对现有疗法没有反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd109240f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案

2017-12-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

“淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)”解读

2017-11-02

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：B细胞淋巴瘤（2017.V4）

2018-05-16

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Am J Hematol：来那度胺单药治疗复发性/难治性套细胞淋巴瘤

2017-09-30

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Duvelisib与免疫检查点抑制剂在B细胞淋巴瘤模型中具有显著协同作用

2018-03-13

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

伴面部肿胀结外鼻型NK/T细胞淋巴瘤死亡1例

2018-12-19

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

蔡清清教授：套细胞淋巴瘤治疗新进展综述

2018-10-30

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-08-11

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性

2017-09-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：B细胞淋巴瘤（2017.V6）

2018-04-15

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Leuk Lymphoma：体重指数可以预测弥漫性大B细胞淋巴瘤的结局吗？

2017-10-21

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：弥漫性大B细胞淋巴瘤的tonic BCR信号通路。

2017-10-20

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究

2018-07-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Haematologica：ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加

2018-05-16

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NEJM：套细胞淋巴瘤患者自体干细胞移植后使用利妥昔单抗维持治疗可延长反应时间

2017-10-23

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Am J Hematol：来那度胺单药治疗复发性/难治性套细胞淋巴瘤，安全且有效

2017-12-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

天津血液肿瘤高峰论坛 |张翼鷟教授：弥漫大B细胞淋巴瘤造血干细胞移植进展

2018-01-25

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【CSCO 2017】黄慧强教授专访：浅谈套细胞淋巴瘤的治疗及BTK抑制剂的疗效

2018-07-23

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

ANN ONCOL：Ⅰ/Ⅱ期NK/T细胞淋巴瘤序贯化疗/放疗与同时放化疗效果相似

2018-11-18

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：携带TP53突变的套细胞淋巴瘤患者对现有疗法没有反应。

2017-11-23

科室
- - 订阅+
  - 更多科室
工具
服务